CVRx, Inc.

NASDAQ•CVRX

CEO: Mr. Kevin Hykes

セクター: Healthcare

業種: Medical - Devices

上場日: 2021-06-30

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

連絡先情報

9201 West Broadway Avenue, Suite 650, Minneapolis, MN, 55445, United States

763-416-2840

www.cvrx.com

時価総額

$223.39M

PER (TTM)

-4.2

29.5

配当利回り

52週高値

$13.34

52週安値

$4.30

52週レンジ

46%

順位61Top 91.5%

2.0

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 2 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q4 2025 データ

売上高

$16.02M+0.00%

直近4四半期の推移

EPS

-$0.46+0.00%

直近4四半期の推移

フリーCF

-$9.83M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Revenue Growth 10% Revenue reached $56.7M USD, growing 10% over prior year; U.S. sales up 10% to $51.9M USD.

Gross Margin Improvement Gross profit increased 13% to $48.3M USD; Gross margin improved to 85% from 84% due to efficiency.

Operating Loss Narrowed Operating loss narrowed 14% to $51.3M USD; Net loss decreased 11% to $53.3M USD for 2025.

Sales Territory Expansion U.S. implanting centers grew to 252 from 223; U.S. sales territories expanded to 53 from 48.

リスク要因

Sustained Operating Losses History of significant net losses ($53.3M USD in 2025) expected to continue, impacting capital raising ability.

Single Product Dependency Highly dependent on Barostim sales; failure to increase U.S. market acceptance materially affects liquidity and results.

Limited Sales Experience Limited commercial sales experience; inability to retain or grow sales capabilities prevents sustained increasing product revenue.

Supply Chain Vulnerability Reliance on limited third-party suppliers for critical components creates vulnerability to shortages and performance degradation.

見通し

Expanded Clinical Trial Initiated BENEFIT-HF trial in Jan 2026 to evaluate expanded population; success could raise U.S. market to $30.5B.

Future Financing Secured Borrowed $10.0M in Jan 2026; maintains ATM capacity up to $50.0M for future commercialization investments.

R&D Focus Areas Near-term R&D focuses on technological advancement; long-term goal is expanding indications to hypertension and arrhythmias.

Sales Force Growth Plan Plan to expand U.S. direct sales force and increase payer awareness to drive future revenue growth.

同業比較

売上高 (TTM)

OMI

$2.76B

-41.0%

INGN

$348.67M

+3.9%

VMD

$270.28M

+20.5%

粗利益率 (最新四半期)

PRQR

100.0%

+0.0pp

OMI

93.9%

-2.1pp

SGHT

87.3%

+2.5pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
CERS	$430.28M	-27.3	-26.4%	25.4%
VMD	$352.17M	23.1	10.9%	10.6%
FHTX	$332.16M	-5.0	105.5%	11.0%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

9.1%

安定成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年4月29日

EPS:-$0.52

売上高:$14.06M

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし